Cascade Chemistry to boost U.S.-made API capacity

Feb. 19, 2021

Cascade Chemistry, an Oregon-based CDMO, announced that it will build new facilities designed to increase the company’s capacity to manufacture APIs under cGMP.

The CDMO will spend $14 million on new facilities, expected to be operational in the first quarter of 2022. Ultimately, the project will increase the company’s floor space almost three-fold and significantly add to its cGMP manufacturing capacity and scale. The expansion also includes 2,200 square feet of new analytical labs, a robust quality system and additional office space.

The 28,000-square-foot building currently under construction will initially include five suites for phase 1 and phase 2 cGMP manufacturing with flow hydrogenation and reactors up to 400 liters. Additional capacity for API phase 3 and commercial scale cGMP manufacturing up to 1,000 liters will be added in 2022. The second building, with 7,000 square feet, is reserved for future expansion.

The expansion comes amid ongoing calls from U.S. policymakers to bring more API and generic drug manufacturing back to U.S. shores. In the last few years, the number of generic API facilities identified in the U.S. has remained stagnant (81 for fiscal year 2021, 76 in 2020, and 79 in both 2019 and 2018) while the number of international facilities continues to climb (583 were identified for fiscal year 2021, up from 548 in 2020, 534 in 2019 and 513 in 2018).

Read the press release